For importers, the active duty problem remains Proclamation 11020's Section 232 regime. The 301 risk is different. It is a possible country-level layer that could be used either to extract UK-style pricing commitments or to stack additional duties on top of the existing 232 architecture.
The structure is simple. Section 232 is the tariff. Drug-pricing Section 301 is the record-building track. The legal weakness is still the bridge from a generally applicable healthcare-reimbursement regime to an "unreasonable or discriminatory" practice that burdens U.S. commerce under Section 301(b).
What changed
The sequence matters. The Section 301-relevant drug-pricing record did not begin with the June 2026 congressional letters. USTR opened the record in May 2025. It announced the request on May 23 and published the Federal Register notice on May 30 under docket USTR-2025-0011. The notice, issued under Executive Order 14297, invited submissions on foreign acts, policies, or practices that may be unreasonable or discriminatory and that may force American patients to bear a disproportionate share of global pharmaceutical research and development.
The UK arrangement set the template. On December 1, 2025 the US and UK announced an understanding on pharmaceutical pricing, with the text published April 2, 2026. The UK accepted higher pricing commitments for new medicines and broader life-sciences commitments. In exchange, the US committed to a tariff-forbearance pathway for covered UK pharmaceutical products and medical technologies, with the detailed timing and scope split across Section 232 and Section 301 commitments through January 19, 2029. That exchange is the model the letters want replicated.
The June letters play a different role. They are acceleration and scope pressure rather than a start signal. The House letter of June 10, 2026 pushes USTR to move the drug-pricing record on an accelerated timeframe. Its 48 members, led by Rep. Vern Buchanan (R-FL, Ways and Means Vice Chair and Health Subcommittee Chair) and including 18 Ways and Means members, name Germany, Switzerland, Japan, France, and Canada, and assert that more than 70 percent of patented pharmaceutical profits in OECD countries come from U.S. sales though the US is one-third of OECD GDP. That 70% figure is an advocacy estimate. The closest verified data point is the HHS and ASPE finding that the US accounted for 78% of OECD sales of the top 50 US drugs in 2022, which reflects sales rather than profits. The Senate letter of June 16, 2026, led by Sen. Todd Young with 23 Senate Republicans, urges the administration to move quickly and treats the US-UK arrangement as the template to replicate, singling out Germany for recently announced cuts to drug prices and reimbursement.
What is already live
The near-term duty math runs through the Section 232 proclamation rather than the drug-pricing 301. Proclamation 11020, signed April 2, 2026, sets a 100% ad valorem duty on patented pharmaceuticals and associated APIs in Annex I, with tiered relief. A Commerce-approved onshoring plan cuts the rate to 20% until it reverts to 100% on April 2, 2030. Products of Japan, the EU, Korea, and Switzerland or Liechtenstein carry a 15% partner rate. An onshoring plan combined with an HHS MFN pricing agreement reaches 0% through January 20, 2029. Orphan, nuclear-medicine, plasma-derived, fertility, cell and gene products, ADCs, and CBRN countermeasures are carved out at 0%. Generics are excluded for now, subject to a Commerce one-year review.
The effective dates are July 31, 2026 for Annex III companies and September 29, 2026 for all others. Relief is a negotiated, company-specific process rather than a product-exclusion process, and the Commerce and BIS procedures published in the Federal Register on May 13, 2026 set an application deadline of June 12, 2026, now passed. Drawback is available, and FTZ admissions require privileged foreign status.
UK-origin covered products sit on a separate tariff-forbearance pathway rather than the ordinary 232 rate grid. Under the UK arrangement, the United States commits to no Section 232 tariffs on UK pharmaceutical products from January 1, 2026 through January 19, 2029, subject to company adherence to the MFN and tariff agreements, and to no additional Section 301 tariffs on UK pharmaceutical products from December 1, 2025 through January 19, 2029. UK medical technologies receive parallel forbearance from additional Section 232 or Section 301 tariffs from December 1, 2025 through January 19, 2029.
The practical task is to classify product coverage, confirm origin and Annex status, model the 232 tier, and watch how the drug-pricing 301 record develops toward a possible country-level layer.
What the pricing-based 301 record still needs to prove
There is no clear precedent for using Section 301 as a tariff lever against a foreign country's generally applicable drug-reimbursement or price-control regime. Prior pharma-related 301 actions were IP cases. The 1988 Brazilian Pharmaceuticals action concerned the absence of patent protection rather than price controls. Foreign pricing complaints have historically traveled through PhRMA's Special 301 market-access filings, and never converted into a 301 pricing enforcement action with retaliatory tariffs.
The Special 301 bridge is the weak point. The senators lean on the 2026 Special 301 Report to confirm foreign price suppression. Special 301 can discuss pricing, because USTR's mandate reaches both IP protection and the fair and equitable market access of IP-reliant persons. The problem is the bridge. A Special 301 market-access concern does not itself establish that a generally applicable reimbursement regime is "unreasonable or discriminatory" and burdens U.S. commerce under Section 301(b). The supporting record is also thin, because the NTE pharmaceutical-pricing entries describe diffuse practices without citing specific statutes, unlike the digital-trade entries that name the DSA, DMA, and GDPR. A Special 301 listing cannot itself substitute for a Section 301 record. The open USTR docket helps with process, but it does not solve the merits problem. USTR still has to connect specific foreign pricing practices to the statutory Section 301(b) standard.
A generally applicable reimbursement or HTA regime is not immune from Section 301 merely because it applies equally to domestic and foreign manufacturers. But that fact raises USTR's burden, because it would need to show not simply low prices but why the regime is unreasonable in trade-law terms and how it burdens or restricts U.S. commerce. The administration's own CMS Innovation Center models, GENEROUS, GLOBE, and GUARD, use international reference-pricing logic, which makes it harder to argue that comparable foreign pricing tools are inherently unreasonable.
The Germany example is useful but unstable. Reuters reported on June 15, one day before the Senate letter, that Germany was moving away from variable drug discounts toward fixed discounts after industry pushback, while the health ministry said the legislation was not final. That does not eliminate the pricing dispute, but it weakens the letter's lead factual hook.
The hard statutory question is not USTR's view of foreign drug-pricing systems but whether it can build a country-specific record showing that a generally applicable healthcare-reimbursement regime qualifies as "unreasonable or discriminatory" and burdens or restricts U.S. commerce under Section 301(b). That is a record-building problem rather than a rhetorical one.
Why it still matters
The drug-pricing 301 track matters because it is leverage as much as remedy. The June letters make that explicit. The goal is to replicate the UK deal, using the investigation, the record, or the threat of action as bargaining leverage to extract higher foreign prices and investment rather than simply to impose a trade remedy.
The post-IEEPA setting explains the pressure. After the Supreme Court invalidated IEEPA tariffs 6-3 in Learning Resources, Inc. v. Trump on February 20, 2026, Section 232 and Section 301 became the administration's more durable tariff vehicles, and the drug-pricing 301 was one of several themes USTR floated soon after. The Supreme Court's June 15 denial of certiorari in HMTX Industries LLC v. United States left intact the Federal Circuit ruling that upheld the expansion of China Section 301 tariffs on Lists 3 and 4A. A cert denial is not a merits ruling, but courts have shown substantial practical deference to well-papered Section 301 actions, so the litigation backdrop would favor USTR if it builds the record.
The practitioner's real concern is stacking. If a pricing-based 301 action lands on Germany or Japan, it would add country-level tariffs, or a negotiated pricing concession, on top of the existing 232 regime, compounding exposure for importers already modeling the 15% partner rate.
Practitioner watch list
For now, treat Section 232 as the active event. Confirm whether covered products fall in Annex I, model exposure across the 100%, 20%, 15%, and 0% tiers, and confirm Annex III status, which sets the July 31 against September 29 effective date. Companies that filed onshoring applications by June 12 should track the Commerce case-by-case review, which carries no statutory decision deadline, and CBP implementation. For EU, Japan, Korea, and Switzerland-origin patented pharma, build the 15% rate into landed-cost models now, and for UK-origin, confirm tariff-free treatment under the arrangement's conditional pathway.
On the 301 side, the decisive trigger is no longer whether USTR opens the drug-pricing record, because it already has. The question is how USTR builds and uses the record, including which countries, which pricing practices, and which products it targets, what burden on U.S. commerce it asserts, and whether the agency moves from comments to findings, negotiated commitments, or proposed action. Germany's final reform text bears watching, because the June 15 shift from variable to fixed discounting undercuts the letter's lead example. Bilateral deals with the EU, Japan, or Switzerland that replicate the UK template would moot a 301 action against those partners, much as the UK arrangement already forecloses UK-targeted pricing action through January 2029. A 232 extension to generics in Commerce's one-year report would widen the at-risk importer population materially.
Caveats
USTR has opened a drug-pricing record under Executive Order 14297, but no Section 301 drug-pricing tariff has been imposed and no final Section 301 findings have been issued as of this writing. The active issue is whether USTR converts that record into findings, proposed action, or UK-style negotiated commitments.
No court has adjudicated the article's novelty and fragility assessment. The strongest critiques come from Public Citizen, KEI, Prof. Sean Flynn, and, on the general elasticity of Section 301, Cato. Courts have not ruled on a pricing-based 301, and the deference record cuts toward survivability.
IEEPA refund and remedy uncertainty is a separate workstream in CIT and CBP processing and should not be conflated with 232 or any future 301 duties.
Several figures, including the roughly 70 to 78% of OECD patented pharmaceutical sales from the US, onshoring-applicant counts, and illustrative duty gaps, originate in advocacy letters, agency information-collection estimates, or law-firm alerts, and should be treated as estimates rather than audited figures.